A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular Carcinoma
Trial details
- Registry ID
- NCT06679985
- Phase
- Phase 2
Drug identity checked against registry records
Also recorded as CHS-388; SRF388
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Trial of Casdozokitug in Combination With Toripalimab Plus Bevacizumab in Participants With Unresectable and/or Locally Advanced or Metastatic Hepatocellular CarcinomaNCT06679985 | CHRS | Phase 2 | Active not recruiting | 2027-09Estimated |
| Trial of Atezolizumab and Bevacizumab With CHS-388 or Placebo in Patients With Hepatocellular CarcinomaNCT05359861 | CHRS | Phase 2 | Terminated | 2025-06-30Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |